This report was first published by Endpoints News. To see the original version, click here
Many developers of obesity drugs are fond of saying that it’s not a competition to produce the strongest and fastest level of weight loss. They had better hope they’re right, because if it is a competition, Eli Lilly is winning.
The Indianapolis drugmaker said Thursday that its triple agonist retatrutide allowed obesity patients to lose about a quarter of their weight after taking the shot for 80 weeks — about a year and a half. This is the strongest weight loss data yet in a Phase 3 trial in a pure obesity population.
您已阅读16%（613字），剩余84%（3116字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。